Open House Original discount contracts 2025-19 - Tafamidis Text automatically translated in your browsing language Automatically translated

TK pursues the objective of concluding rebate agreements with all suitable pharmaceutical entrepreneurs in accordance with § 130c(1) SGB V on the active substance tafamidis (for the division of lots, see the respective lot names). The contract is concluded within the framework of the Open House original procedure of the TK: Individual negotiations on contract contents are not conducted, uniform conditions apply. TK does not guarantee any exclusivity to individual contractual partners. The contract duration is a maximum of 24 months starting from 01.06.2025. The contract ends at the latest on 31.05.2027, regardless of the date of conclusion of the contract. In the event of patent expiration/expiration of market exclusivity before the above-mentioned end date, the contract shall automatically end at the end of the month of patent expiration/market exclusivity. It is possible to join this open-house original procedure at any time within the term of the contract. Due to the existence of industrial property rights with regard to the active substance or combination of active substances that are the subject of these proceedings, the participation and contractual documents are only made available to pharmaceutical entrepreneurs who offer/place on the market medicinal products relating to the active substance or combination of active substances that are the subject of these proceedings or make it credible to TK that they intend to offer/place on the market such medicinal products within the term of the contract. The information provided on the period of validity is not relevant in the present case and is exclusively due to the mandatory requirements of the form. All further information can be found in the participation and contract documents. Text automatically translated in your browsing language Automatically translated

33600000 - Pharmaceutical products